MET and carcinosarcoma: Together, we show that TRIM24-mediated, epigenetic activation of c-Met is disrupted by selective inhibitors, Crizotinib and PHA-665752, in a dose-dependent manner in primary metaplastic carcinosarcoma tumor cells.